codeine phosphate 240 mg/d. The introduction of sulphasalazine coincided with a clinical and serological remission (see Figure 1 ). Two weeks after starting sulphasalazine she developed faecal obstruction. Her medication (apart from prednisolone) was withdrawn and the obstruction was relieved with enemas. Her diarrhoea returned, but ceased when sulphasalazine was reintroduced. She remained in clinical and serological remission (despite a gradual decrease in the dose of prednisolone) until December 1986, when she relapsed. Azathioprine at a maximally tolerated dose of 150 mg per day and an increase in the dose of prednisolone induced a short remission, but her diarrhoea and buccal ulceration returned in January 1987. Cyclosporin A was added to her treatment at a dose of 10 mg/kg, her symptoms improved within 3 days. Cyclosporin was stopped after 6 weeks and she has remained well since that time.
Discussion
The diagnosis of'Behcet's disease is based on clinical criteria because there is no specific diagnostic test. The classification of Mason and Barnes! is widely used and Behcet's disease is diagnosed when any 3 of the major diagnostic criteria are present. According to this system our patient had 4 of the diagnostic criteria for the diagnosis of Behcet's disease (orogenital ulceration, skin lesions and ocular involvement) confirming the diagnosis.
The co-existence of colonic and oesophageal ulcers in Behcet's disease is rare and has been the subject of a small number of case reports", These reports describe severe, symptomatic oesophageal lesions: our patient had minimal dysphagia and gastroscopy showed that the oesophagus was diseased. This suggests that oesophageal involvement in Behcet's disease may be more common than is presently believed.
The treatment of Behcet's colitis is controversial: steroids are the major therapeutic agent, but there is concern that they may provoke colonic perforation-, The role of anti-mitotic drugs has not been determined. Our case confirms previous reports that sulphasalazine may be of value in the treatment of this condition" because on 2 separate occasions the introduction of the drug was associated with improvement.
Cyclosporin A has been shown to be of value in the treatment of ocular Beheet's", To our knowledge it has never been used in the treatment of the colonic complications, but it has been shown to be a useful treatment for refractory Crohn's disease". Our case suggests that it may be of value in the treatment of Beheet's colitis. We describe a patient with autoimmune thyroid disease in whom multiple autoantibodies caused a fluctuating clinical state and interference with hormone assays.
Case report
A 31-year-old male presented in 1982 with lethargy and cold intolerance. On examination he had a small goitre, mild exophthalmos, dry skin, hoarse voice and slow relaxing reflexes. His serum total thyroxine (T4) was 126 nmolll (normal range 50-130nmol/l) and TSH >64mUIL «6 mUlL).
Thyroid microsomal antibodies were positive 1 : 6 500 000. He was treated with thyroxine 150 Ilg daily and became clinically euthyroid although the exophthalmos persisted.
Two years later in 1984, he developed purpura. His platelet count was 20x10 91l and platelet antibodies were positive. He was started on 40 mg per day of'prednisolone with a good response. On decreasing the dose of thyroxine to 50 Ilghe became clinically hypothyroid again and TSH rose to 9.6 mUll although his serum T4 was 117 nmolll. He became euthyroid again on 150 Ilg of thyroxine. Six months later his thrombocytopenia relapsed on prednisolone 10 mg daily and he underwent a splenectomy. One month later he developed tremors, sweating and heat intolerance. He had a tachycardia but no goitre and his exophthalmos was unchanged. His serum free thyroxine <FI'4, Amersham, UK) was > 106 pmolll (8.8-23.0), total T3 8.8 nmolll « 3) and TSH 1 mUll. Thyroxine replacement was stopped but a month later he remained clinically and biochemically hyperthyroid with a serum FT4 > 106 pmolll. His serum FT4 measured by an equilibrium dialysis method was 46.8 pmolll (8.8-23.0) and thyroid binding globulin (TBG) 10 ng/l (7-17). He was treated with carbimazole and 6 months later was clinically Because of the discrepancy between the serum FT4 and TSH, his serum was assessed for autoantibody interference in the FT4 assay by a previously described method'. A 40% binding by the patient's serum of the FT4 tracer was found as compared with only 7% binding by control serum indicating the presence in the patient's serum of antibody which binds the analogue label in the FT4 Amerlex-M Kit. Similar results were obtained using 125 1 labelled thyroxine as well as the Amerlex FT3 analogue label.
Over the next year his clinical state fluctuated with intermittent symptoms and signs of both hyperthyroidism and hypothyroidism. Adjustments in the dose of carbimazole (between 5 and 20 mg daily) had to be made according to the clinical state of the patient, as hormone assays did not reflect the true clinical state of the patient.
After 18 months' treatment, carbimazole was stopped. One year later the patient remains asymptomatic and clinically euthyroid. His serum FT4 is > 120 pmol/l and TSH >50 mUlL (a 2 site sandwich immunoradiometric assay using reagents supplied by the North East Thames RegionImmunoassay Unit). The following further investigations have been carried out: (1)TSH receptor antibody (TRAb)360 mUlml (NR< 10 mU/ml MRC LATS standard unit squivalentsf', (2) Ophthalmopathy immunoglobulin (OIg) positive 1.290 (NR <0.602). Table 1 illustrates some ofthe changes in clinical and biochemical status ofthe patient over the last year.
Discussion
We have described a patient with autoimmune thyroid disease in whom a variety of autoantibodies caused at least 3 distinct clinical problems: (1) Hashitoxicosisw with rapid fluctuations in thyroid status; (2)antibody interference with the FT4 and FT3 radioimmunoassay and possibly the TSH immunoradiometric assay as well and (3) hypothyroidism despite a significant titre ofTSH receptor antibodies (TRAb). These features made management based on standard laboratory tests difficult. Hashitoxicosisw and autoantibody interference with hormone assays have been previously well described, although not in the same patient. Interference with the IRMA TSH assay is, however, to our knowledge, unknown.
Hypothyroidism in the presence of TRAb has also been described, but only in patients treated with radio-iodine for previous thyrotoxicosis. We have not measured TSH receptor blocking activity" in our patient's serum but it would seem reasonable to speculate that the patient has such antibodies. The relative proportion of TSH receptor stimulating or blocking antibody at anyone point in time would determine the clinical state.
We conclude that in patients with multiple autoantibodies assessment of the wildly fluctuating clinical state may be impossible by standard laboratory tests. Despite spectacular advances in the measurement of hormone concentrations, clinical signs and symptoms still have a role to play in management of patients with thyroid disease.
